Drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
in excess of 3 metres (9.8 feet) have been collected on several occasions, representing probable ages in excess of 400 years (Fisher, 1995). Vestimentiferan tube worm spawning is not seasonal, and recruitment is episodic. Tubeworms are either male or female. One recent discovery indicates that the spawning of female Lamellibrachia appears to have produced a unique association with the large bivalve Acesta bullisi, which lives permanently attached to the anterior tube opening of the tubeworm, and feeds on the periodic egg release (Järnegren et al., 2005). This close association between the bivalves and tubeworms was discovered in 1984 (Boland, 1986) but not fully explained. Virtually all mature Acesta individuals are found on female rather than male tubeworms. This evidence and other experiments by Järnegren et al. (2005) seem to have solved this mystery. Growth rates for methanotrophic mussels at cold seep sites have been reported (Fisher, 1995). General growth rates were found to be relatively high. Adult mussel growth rates were similar to mussels from a littoral environment at similar temperatures. Fisher also found that juvenile mussels at hydrocarbon seeps initially grow rapidly, but the growth rate drops markedly in adults; they grow to reproductive size very quickly. Both individuals and communities appear to be very long-lived. These methane-dependent mussels have strict chemical requirements that tie them to areas of the most active seepage in the Gulf of Mexico.
Manchester's Revolutionary 2D Material at The University of Manchester Graphene at The Periodic Table of Videos (University of Nottingham) Graphene: Patent surge reveals global race 'Engineering Controls for Nano-scale Graphene Platelets During Manufacturing and Handling Processes' (PDF) Band structure of graphene (PDF).
=== Sprouting angiogenesis === Sprouting angiogenesis was the first identified form of angiogenesis and because of this, it is much more understood than intussusceptive angiogenesis. It occurs in several well-characterized stages. The initial signal comes from tissue areas that are devoid of vasculature. The hypoxia that is noted in these areas causes the tissues to demand the presence of nutrients and oxygen that will allow the tissue to carry out metabolic activities. Because of this, parenchymal cells will secrete vascular endothelial growth factor (VEGF-A) which is a proangiogenic growth factor. These biological signals activate receptors on endothelial cells present in pre-existing blood vessels. Second, the activated endothelial cells, also known as tip cells, begin to release enzymes called proteases that degrade the basement membrane to allow endothelial cells to escape from the original (parent) vessel walls. The endothelial cells then proliferate into the surrounding matrix and form solid sprouts connecting neighboring vessels. The cells that are proliferating are located behind the tip cells and are known as stalk cells. The proliferation of these cells allows the capillary sprout to grow in length simultaneously. As sprouts extend toward the source of the angiogenic stimulus, endothelial cells migrate in tandem, using adhesion molecules called integrins. These sprouts then form loops to become a full-fledged vessel lumen as cells migrate to the site of angiogenesis.
Sources: en.wikipedia.org
== In plants == While most plant species are perennial, about 6% follow an annual life cycle, living for only one growing season. The annual life cycle has evolved in over 120 plant families across the entire angiosperm phylogeny. Notably, the prevalence of annual species increases under hot-dry summer conditions in different families including Asteraceae, Brassicaceae, Fabaceae, and Poaceae. Leaves have evolved multiple times - see Evolutionary history of plants. They have evolved not only in land plants, but also in various algae, like kelp. Prickles, thorns and spines are all modified plant tissues that have evolved to prevent or limit herbivory, these structures have evolved independently a number of times. Stimulant toxins: plants which are only distantly related to each other, such as coffee, tea, kola and yerba mate produce caffeine to deter predators. The aerial rootlets found in ivy (Hedera) are similar to those of the climbing hydrangea (Hydrangea petiolaris) and some other vines. These rootlets are not derived from a common ancestor but have the same function of clinging to whatever support is available. Flowering plants (Delphinium, Aerangis, Tropaeolum and others) from different regions form tube-like spurs that contain nectar. This is why insects from one place sometimes can feed on plants from another place that have a structure like the flower, which is the traditional source of food for the animal.
=== Ha === Fritz Haber (1868–1934), German chemist, 1918 Nobel Prize in Chemistry, father of the Haber process Dorothy Hahn (1876–1950), early American organic chemist and ultraviolet spectroscopist Otto Hahn (1879–1968), German chemist, discoverer of nuclear fission, 1944 Nobel Prize in Chemistry, father of nuclear chemistry Sossina M. Haile (born 1966), American chemist notable for developing the first solid acid fuel cells Naomi Halas (PhD 1987), American biochemist focusing on nanoshells and nanophotonics John Burdon Sanderson Haldane (1892–1962), British and Indian biochemist, geneticist and evolutionary biologist Charles Martin Hall (1863–1914), American chemist known for the Hall-Héroult process for inexpensive production of aluminum Frances Mary Hamer (1894–1980), British chemist who specialized in photographic sensitization compounds George S. Hammond (1921–2005), American chemist, famous for Hammond's postulate as part of the general theory of the transition state in chemical reactions Arthur Harden (1865–1940), English biochemist, Nobel Prize in Chemistry in 1929 for work on the fermentation of sugar and fermentative enzymes Elizabeth Hardy (1915–2008), Canadian-American chemist who discovered the Cope rearrangement of dienes Anna J.
=== Prevention of suicide === Lithium has been shown to reduce the risk of suicide in individuals with bipolar disorder or major depression to close to the same level as that of the general population. It is thought to exert this effect by treating the underlying mood disorder and through a reduction in impulsivity and aggressiveness. Lithium is proven to reduce the risk of suicide in mood disorders by 87% in randomized double-blind placebo-controlled trials. Some meta-analyses have not found a statistically significant association between lithium and a reduction in suicide, however these meta-analyses are disputed. Some evidence suggests lithium is effective in significantly reducing the risk of self-harm and unintentional injury for bipolar disorder in comparison to no treatment and to antipsychotics or valproate. In addition, lithium decreases all-cause mortality in people with bipolar disorder. The increased presence of trace amounts of lithium in drinking water is correlated with lower overall suicide rates, especially among men. Lithium in drinking water is also associated with lower rates of homicide, rape, drug arrests, and other crimes.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.